Shen Lian Biomedical(SH:688098) Ge Long Hui A P P·2025-08-19 02:36Core Viewpoint - Shenlian Bio (688098.SH) has experienced a significant stock price increase, reaching a new high since March 2021, with a 20% limit up for three consecutive days, currently priced at 15.4 yuan [1] Company Summary - Shenlian Bio announced that there are no undisclosed significant matters after self-examination and verification with its controlling shareholder and actual controller [1] - The company's production and operations are normal, with no major changes reported [1] - The main business of the company focuses on veterinary biological products, while its innovative drug pipeline, including AIDS monoclonal antibodies, is independently operated by its joint venture, Yangzhou Shizhi Source Biotechnology Co., Ltd. [1] - The related business has characteristics of long R&D cycles, high investment, and significant R&D risks [1]